Introduction {#S1}
============

Hereditary tyrosinemia type I (HT1)(OMIM 276700) is an autosomal recessive disorder caused by genetic defects in the fumarylacetoacetate hydrolase (*FAH*), the last enzyme in the catabolic pathway of tyrosine[@R1]. The accumulation of toxic metabolites in liver is believed to cause liver failure, cirrhosis, hepatocellular carcinoma, and death.

Several patients (28% and up to 100% in the Saguenay-Lac-Saint-Jean region of Quebec)[@R2] carry the *FAH* c.1062+5G\>A mutation at the exon 12 5'splice site (ss). Investigations in patients[@R3] and with minigenes[@R4] demonstrated that this change induces exon 12 and exons 12-13 skipping as well as partial intron 12 inclusion with usage of an intronic cryptic 5'ss, thus explaining the *FAH* immune-negativity of liver sections from homozygotes. Differently, the presence of the new c.1061C\>A (c.P354Q) somatic change with the c1062+5G\>A mutation was found to be associated with hepatic FAH immune-positivity[@R5]. Here we demonstrated the compensatory effect of the c.1061C\>A change in promoting FAH immune-positivity, which also renders the defective *FAH* 5'ss highly responsive to correction by a compensatory U1snRNA.

Material and Methods {#S2}
====================

To create the pFAHwt minigenes, the 804-bp genomic fragment spanning *FAH* intron 11 (from position c.960-357) trough intron 12 (until position c.1062+327) was amplified from genomic DNA of a normal subject using high-fidelity PfuI DNA-Polymerase (Transgenomic, Glasgow, UK) with primers ^5'^[CATATG]{.ul}GACTGGAGGGTGTTCCCA^3'^ (forward) and ^5'^[CATATG]{.ul}CCACCTCATCCTGGGAGGGT^3'^ (reverse), and cloned in the pTB expression vector by exploiting the *NdeI* restriction site within primers (underlined)[@R6]. The mutant pFAH constructs were generated by site-directed mutagenesis (QuickChange II XL Site directed Mutagenesis Kit; Agilent Technologies, Santa Clara, CA, USA) using primers ^5'^CATCAGCGGGCCGGTGAATATCTGGCTGCACTGAG^3'^ and ^5'^CTCAGTGCAGCCAGATATTCACCGGCCCGCTGATG^3'^, to introduce the c.1062+5G\>A change, and primers ^5'^CCATCAGCGGGCDGGTGAGTATCTG^3'^ and ^5'^CAGATACTCACCHGCCCGCTGATGG^3'^, to introduce the c.1061C\>A/T/G changes. The pU1^FAH^ expression vector was created as previously described[@R7].

HepG2 cells were transfected with Lipofectamine 2000 (ThermoFisher SCIENTIFIC, Carlsbad, CA, USA) in 12-well plate with pFAH minigenes (1 μg) alone or with a molar excess (1.5X) of pU1FAH. Total RNA extraction was performed 24 hours post-transfection using TRIreagent (ThermoFisher SCIENTIFIC) and reverse transcribed using the M-MLV (ThermoFisher SCIENTIFIC). The primer couples α-2,3 (^5'^CAACTTCAAGCTCCTAAGCCA CTGC^3'^) and Bra (^5'^TAGGATCCGGTCACCAGGAAGTTGGTTAAATCA^3'^) in the neighboring exons of the hybrid minigene, or FAH12F in exon 12 (^5'^ACATGTACTGGACG ATGCTGCA^3'^) and Bra, indicated by arrows in [figure 1](#F1){ref-type="fig"}, were used for the RT-PCR that was run for 40 cycles at the following conditions: 95°C for 30 s, 56 °C for 30 s, 72°C for 40 s. The densitometric analysis of bands was performed using ImageJ software.

For the denaturing capillary electrophoresis[@R8] on the automated ABI-3100 instrument, the RT-PCR has been performed with primer α-2,3 and Bra, the latter labelled with FAM dye (Bra^FAM^).

Results and Discussion {#S3}
======================

To dissect the mechanisms triggered by the HT1-causing *FAH* c.1062+5G\>A mutation alone or in combination with the somatic *FAH* c.1061C\>A change we performed expression studies with *FAH* minigenes ([Figure 1A](#F1){ref-type="fig"}). Since the splicing process is cell specific, the experiments were conducted into human hepatoma cell lines (HepG2), being liver the major physiologic site of FAH synthesis.

Consistently with previous data[@R3]--[@R5] the c.1062+5G\>A mutation, as revealed by both densitometric analysis of bands or fluorescent RT-PCR followed by denaturing capillary electrophoresis, induced exon 12 skipping (\~31% of total transcripts) and partial intron retention (\~69%), with no traces of correct transcripts ([Figure 1B](#F1){ref-type="fig"}, upper panel and [Figure 1C](#F1){ref-type="fig"}), a splicing profile that validated our experimental approach. Interestingly, the introduction of the c.1061C\>A substitution in the c.1062+5G\>A background partially rescued the defective 5'ss recognition and led to residual levels of correct transcripts (5,2±0,9%)([Figure 1C](#F1){ref-type="fig"}), which was further demonstrated by a RT-PCR focused on exon 12 ([Figure 1B](#F1){ref-type="fig"}, lower panel).

Computational analysis of 5'ss scores ([Figure 1A](#F1){ref-type="fig"}, Table), an estimate of the complementarity between the 5'ss sequence and the 5' tail of the key spliceosomal U1 small nuclear RNA (U1snRNA)[@R9], predicts that the c.1061C\>A change, but not the other c.1061C\>T or c.1061C\>G substitutions, strengthen the affected 5'ss. This would favor the utilization of the mutated 5'ss and the production of correct transcripts. Consistently, the impact of the other changes (c.1061C\>T or c.1061C\>G) on the splicing profile of the c.1062+5G\>A mutation was negligible ([Figure 1B](#F1){ref-type="fig"}).

Altogether these observations demonstrated that in the c.1062+5G\>A background the c.1061C\>A somatic change accounts for trace levels of correct transcripts. In turn, this would explain the residual FAH protein expression and immune-positivity in HT1 liver nodules with the above mentioned genetic profile, thus providing an additional mechanism leading to FAH immune-reactive mosaicism. It is worth noting that the FAH immune-reactive mosaicism has been so far attributed to the reversion of the mutated allele into the wild type[@R10], as also reported in other diseases[@R11]. Both mechanisms would be favored by the high mutation rate of HT1 hepatocytes,[@R11] followed by positive selection of FAH-expressing hepatocites, which would lead to the formation of FAH-immunopositive nodules.

Splicing mutations, relatively frequent in metabolic disorders (<http://www.hgmd.cf.ac.uk>) as well as in others human diseases[@R12], represent potential targets for RNA-based therapies. Several studies have indicated that splicing mutations can be counteracted by engineered U1snRNAs with increased complementarity with the 5'ss of the defective exon[@R13]--[@R15]. We therefore created a U1snRNA variant specifically designed on the *FAH* exon 12 5'ss (U1^FAH^). However, in co-expression experiment, the compensatory U1^FAH^ was ineffective on the c.1062+5G\>A mutation, which demonstrated the severe impairment of the 5'ss recognition. Notably, and consistently with a slightly improved 5'ss, the combination of the HT1-causative mutation with the c.1061C\>A change resulted in remarkable responsiveness to the U1^FAH^ that promoted exon 12 inclusion, as witnessed by the robust synthesis of correct transcripts (62,5±1,2%)([Figure 1B,C](#F1){ref-type="fig"}).

Conclusion {#S4}
==========

Altogether these findings elucidate the molecular basis of HT1 caused by the frequent *FAH* c.1062+5G\>A mutation, and demonstrate the compensatory effect of the c.1061C\>A change in promoting exon definition, thus unraveling a rare mechanism leading to FAH immune-reactive mosaicism.
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![Splicing patterns of *FAH* minigenes in HepG2\
A) Schematic representation of the *FAH* minigene, cloned within the *NdeI* sites (indicated) in the pTB vector, with the sequence of the exon 12 5'ss and of the investigated changes as well as of the 5' tail of the compensatory U1^FAH^. The asterisk indicates the crypric 5'ss.\
The table reports the predicted score of the wild type or mutated 5'ss (<http://www.fruitfly.org/seq_tools/splice.html>).\
B) *FAH* splicing patterns in HepG2 cells transiently transfected with pFAH minigenes (1 μg) alone or with a molar excess (1.5X) of pU1FAH. RT-PCR was conducted with primers α-2,3 and Bra (upper panel) or primers FAH12F and Bra (lower panel), and amplicons were separated on 2% agarose gel. The scheme of amplicons is reported on the left together with primers used (arrows).\
C) FAH splicing patterns as in the upper panel of section B (lanes 2, 8 and 9) evaluated by fluorescently-labelled RT-PCR with primers α-2,3 and Bra^FAM^, followed by denaturing capillary electrophoresis. The scheme of amplicons and the length (nt) are reported on top. Numbers below peaks indicate the relative amount (%, mean from three independent experiments) of each transcript.](emss-76033-f001){#F1}
